Mark J. Gergen
2016 - Mirati Therapeutics
In 2016, Mark J. Gergen earned a total compensation of $2M as Former Executive Vice President and Chief Operations Officer at Mirati Therapeutics, a 87% increase compared to previous year.
Compensation breakdown
| Option Awards | $1,179,389 |
|---|---|
| Salary | $283,909 |
| Other | $512,747 |
| Total | $1,976,045 |
Gergen received $1.2M in option awards, accounting for 60% of the total pay in 2016.
Gergen also received $283.9K in salary and $512.7K in other compensation.
Rankings
In 2016, Mark J. Gergen's compensation ranked 4,947th out of 14,075 executives tracked by ExecPay. In other words, Gergen earned more than 64.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,947 out of 14,075 | 65th |
Division Manufacturing | 1,765 out of 5,489 | 68th |
Major group Chemicals And Allied Products | 557 out of 1,895 | 71st |
Industry group Drugs | 413 out of 1,538 | 73rd |
Industry Pharmaceutical Preparations | 328 out of 1,176 | 72nd |
Source: SEC filing on April 20, 2017.
Gergen's colleagues
We found five more compensation records of executives who worked with Mark J. Gergen at Mirati Therapeutics in 2016.
2016
Charles Baum
Mirati Therapeutics
Chief Executive Officer
2016
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2016
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2016
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
2016
Chris LeMasters
Mirati Therapeutics